Olawunmi Oyedeji | Oncology | Innovative Research Award

Published on by Global Diseases Research

Innovative Research Award

Olawunmi Oyedeji
The Christie NHS Foundation Trust

                          Olawunmi Oyedeji
Affiliation The Christie NHS Foundation Trust
Country United Kingdom
Scopus ID 58803277000
Documents 2
Citations 2
h-index 2
Subject Area Oncology
Event Global Diseases Research Awards
ORCID 0009-0008-0626-3422

Olawunmi Oyedeji is a researcher affiliated with The Christie NHS Foundation Trust, United Kingdom, whose academic activities contribute to the field of oncology research. The Innovative Research Award recognizes researchers demonstrating valuable contributions through scientific investigation, clinical advancement, and knowledge development within their respective disciplines. [1]

Abstract

The Innovative Research Award highlights academic excellence and meaningful contributions in oncology research. Olawunmi Oyedeji, affiliated with The Christie NHS Foundation Trust, United Kingdom, represents emerging research activities focused on advancing healthcare knowledge and improving scientific understanding. With documented publications, citations, and research engagement indexed through Scopus, the researcher demonstrates participation in scholarly communication. The award recognizes dedication toward innovative approaches, evidence-based practices, and contributions supporting progress in global disease research and clinical advancement. [1]

Keywords

Oncology Research, Clinical Research, Innovative Research Award, Cancer Research, Healthcare Innovation

Introduction

Oncology research plays an important role in understanding cancer biology, improving diagnosis, and developing effective therapeutic strategies. Researchers working within clinical and academic institutions contribute essential evidence that supports improvements in patient care and healthcare systems. [2]

Research Profile

Olawunmi Oyedeji is associated with The Christie NHS Foundation Trust, a leading healthcare institution in the United Kingdom. The research profile includes two indexed documents, two citations, and an h-index of two according to available Scopus information. [1]

Research Contributions

The researcher’s contributions are positioned within oncology and healthcare research. Scientific contributions in this area support better understanding of diseases, treatment approaches, clinical methodologies, and evidence-based medical practices. Such efforts strengthen collaborative research environments and promote advancement in cancer-related knowledge. [2]

Publications

The researcher has published scholarly documents indexed within Scopus databases. These publications contribute to academic discussions in oncology and related healthcare disciplines. Research outputs provide opportunities for knowledge exchange and future scientific collaboration among international researchers. [3]

Research Impact

Research impact is reflected through scholarly visibility, citation activity, and contribution to scientific literature. The available metrics indicate participation in academic research communication and demonstrate the importance of continued investigation within oncology and clinical sciences. [4]

Award Suitability

The Innovative Research Award recognizes researchers who demonstrate commitment toward scientific advancement and meaningful research activities. Based on the researcher’s oncology-focused profile, institutional affiliation, and academic contributions, Olawunmi Oyedeji represents a suitable candidate for recognition within the Global Diseases Research Awards framework. [4]

Conclusion

Olawunmi Oyedeji’s research profile demonstrates involvement in oncology-related scientific activities through institutional association, publications, and academic indexing. The Innovative Research Award acknowledges continued efforts toward research development and contributions supporting healthcare innovation and global scientific progress.

External Links

References

  1. Elsevier. (n.d.). Scopus author details: Olawunmi Oyedeji, Author ID 58803277000. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=58803277000
  2. Global Diseases Research Awards. (n.d.). Innovative Research Award Information.
    https://globaldiseases.org/
  3. Oisakede, E. O., Oyedeji, O. O., Olawuyi, O. F., Alabi, J. O., Daniel, R. I. A., & Olawade, D. B. (2026). Nanoparticle-mediated cardiotoxicity and nanomedicine interventions in cancer treatment. Nano TransMed, 5, Article 100113.
    https://doi.org/10.1016/j.ntm.2026.100113
  4. Oyedeji, O. O., & Oisakede, E. O. (2026). Radiation-induced rhinosinusitis after treatment of nasopharyngeal and selected sinonasal cancers: A narrative review. Sinusitis, 10(1), Article 100015.
    https://doi.org/10.3390/sinusitis10010015

Evie Carchman | Cancer Prevention | Best Researcher Award

Published on by Global Diseases Research

Dr. Evie Carchman | Cancer prevention | Best Researcher Award 

Associate Professor | University of Wisconsin | United States

Dr. Evie H. Carchman is a distinguished clinician-scientist affiliated with the William S. Middleton Memorial Veterans Hospital in Madison, United States, recognized for her extensive contributions to colorectal and anal disease research. With 68 publications and over 3,700 citations. Dr. Carchman’s work has significantly advanced understanding in areas such as anal cancer prevention, dysplasia detection, and surgical innovation. Her studies on PIK3CA mutations in anal dysplasia, peristaltic contractility in ileal pouch-anal anastomosis (IPAA), and CD4/CD8 ratio as a biomarker in veterans with HIV highlight her multidisciplinary approach that bridges oncology, immunology, and gastrointestinal surgery. As an author and collaborator with over 3,000 co-researchers worldwide, she exemplifies scientific collaboration aimed at improving patient outcomes and translational medicine. Dr. Carchman’s recent publications in reputed journals such as the International Journal of Colorectal Disease, Scientific Reports, and Diseases of the Colon and Rectum emphasize her leadership in identifying novel therapeutic sensitivities in cancer organoids and exploring minimally invasive treatments, including laser hair removal as a primary therapy for pilonidal disease. Her dedication to veterans’ healthcare and public health innovation underscores a career defined by scientific rigor, compassion, and commitment to advancing surgical science and cancer prevention. Through her impactful research, mentorship, and international collaborations, Dr. Evie H. Carchman continues to shape the global landscape of colorectal oncology and preventive medicine, contributing meaningfully to both academic excellence and societal well-being.

Profiles: Scopus | ORCID 


Featured Publications




1. Johnson, H. R., Dietmann, E. C., Praska, C. E., Dennison, K. L., McGregor, S. M., Suter, W., Leverson, G., Murtaza, M., & Carchman, E. H. (2025, November). Detection of PIK3CA mutations in anal dysplasia. Journal of Surgical Research. Advance online publication.


2. Hewitt, A. J., Freeman, M. J., Hayden, D. M., Carchman, E. H., Schweizer, M. L., & Sanger, C. B. (2025, November). Evaluation of anal cancer screening practices among a national cohort of veterans with HIV. Diseases of the Colon & Rectum. Advance online publication.


3. DeZeeuw, A. K., Bassetti, M. F., Carchman, E. H., Heise, C. P., Hayden, D., Lawson, E. H., Sanger, C. B., King, R., LoConte, N. K., Lubner, S. J., et al. (2024, September 3). Carboplatin and paclitaxel chemoradiation for localized anal cancer in patients not eligible for mitomycin and 5-fluorouracil. Cancers, 16(17), 3062. 
Cited by: 1


4. Lozar, T., Wang, W., Gavrielatou, N., Christensen, L., Lambert, P. F., Harari, P. M., Rimm, D. L., Burtness, B., Grasic Kuhar, C., & Carchman, E. H. (2023, November 25). Emerging prognostic and predictive significance of stress keratin 17 in HPV-associated and non HPV-associated human cancers: A scoping review. Viruses, 15(12), 2320. 
Cited by: 4














Dr. Evie H. Carchman’s pioneering research in colorectal and anal cancer prevention integrates molecular oncology, surgical innovation, and translational science to improve patient outcomes. Her work advances global cancer prevention strategies through early detection, precision medicine, and evidence-based clinical practice.